GlobeNewsWire
30 Jul 2026, 02:26 UTC · 2h ago
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
30 Jul 2026, 02:26 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Kuehn Law is investigating Arcus Biosciences (RCUS) for potential breaches of fiduciary duty and self-dealing by officers and directors. — Legal investigations into corporate governance and self-dealing typically create uncertainty and potential liability for the company.
-0.30Kuehn Law is investigating whether officers and directors of CG Oncology (CGON) breached their fiduciary duties. — Law firm investigations into fiduciary breaches signal potential litigation risk for the company's stock.
-0.30Kuehn Law is investigating whether officers and directors of Exelixis (EXEL) breached their fiduciary duties. — Shareholder litigation probes can lead to negative investor sentiment and potential corporate governance costs.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is being investigated by a law firm for potential breaches of fiduciary duty by officers and directors.
The company is being investigated by a law firm for potential breaches of fiduciary duty by officers and directors.
The company is being investigated by a law firm for potential breaches of fiduciary duty and self-dealing by officers and directors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
